FGFR3 biology and skeletal disease.
Portland, United States. In Connect Tissue Res, Nov 2015
Triggered by ligand binding or in some cases mutation, FGFR3 activation involves dimerization of receptor monomers, phosphorylation of specific tyrosine residues in the receptor's kinase domain and in the tightly linked scaffold protein Fibroblast Receptor Factor Substrate 2 (FRS2).
Oncogenic Signaling Adaptor Proteins.
Boston, United States. In J Genet Genomics, Nov 2015
In this review, we focus on the discovery, structure and function, and therapeutic implication of three of these adaptor oncogenes, CRKL, GAB2, and FRS2.
Complexity of FGFR signalling in metastatic urothelial cancer.
Barcelona, Spain. In J Hematol Oncol, 2014
Exploratory biomarker analysis showed FGFR3, FGFR1, FGF-ligand and fibroblast growth factor receptor substrate 2 (FRS2) expression in the patient's tumour, together with the presence of a germ-line mutation in the FGFR3 extracellular binding domain.
Freiburg, Germany. In Febs J, 2010
The growth factor receptor bound 2-associated binder/Daughter of Sevenless, insulin receptor substrate, fibroblast growth factor receptor substrate 2 and downstream of tyrosine kinases protein families fall into this category.
N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling.
Vienna, Austria. In Nat Cell Biol, 2001
Here we show that N-CAM modulates neurite outgrowth and matrix adhesion of beta-cells from pancreatic tumours by assembling a fibroblast-growth-factor receptor-4 (FGFR-4) signalling complex, which consists of N-cadherin, FGFR-4, phospholipase C gamma (PLC-gamma), the adaptor protein FRS2, pp60(c-src), cortactin and growth-associated protein-43 (GAP-43).